Healthcare Purchasing News
  • Magazine
  • Continuing Education
  • Webinars
  • Whitepapers
  • Videos
  • Events
  • Hall of Fame
  • Advertise
  • Source Guide
  • Subscribe
  • Sourcing & Logistics
  • Sterile Processing
  • Surgical & Critical Care
  • Patient Satisfaction
  • Infection Prevention
  • EVS & Facility Services
  • Healthcare IT
  • Regulatory
  • Topics
    Sourcing & LogisticsSterile ProcessingSurgical & Critical CarePatient SatisfactionInfection PreventionEVS & Facility ServicesHealthcare ITRegulatory
    Resources
    HPN Source GuideContinuing EducationWebinarsWhitepapersVideosEventsHall of FameAdvertiseAd Specs
    User Tools
    SubscribeContact UsAbout UseNewsletterMagazinesPrivacy PolicyTerms & Conditions
    https://www.facebook.com/hpnonline
    https://www.linkedin.com/company/healthcare-purchasing-news/
    https://twitter.com/HPN_Online
    1. Patient Satisfaction
    2. Population Health/Care Continuum

    Ultrapotent compound may help treat C. diff, reduce recurrence

    Sept. 25, 2020
    Photo by Chokniti Khongchum from Pexels
    Ultrapotent Compound May Help Treat C Diff, Reduce Recurrence Pic 9 25 20du Pexels Chokniti Khongchum 3938022 Pexels

    Purdue University reported that their researchers have advanced novel compounds that they developed to help treat patients with C. diff, one of only four bacteria considered an urgent threat by the Centers for Disease Control and Prevention. Their work is published in the Journal of Medicinal Chemistry. 

    Clostridioides difficile, or C. diff, is the leading cause of healthcare-associated infection in the U.S. Only two antibiotics, vancomycin and fidaxomicin, are FDA-approved for the treatment of C. diff, but even these therapies suffer from high treatment failure and recurrence. 

    “Our compounds have several advantages, including ultrapotent activities with minimum inhibitory concentration values as low as 0.003 μg/mL,” said Herman O. Sintim, the Drug Discovery Professor of Chemistry in Purdue’s Department of Chemistry. “Our compounds also do not kill good bacteria at concentrations that kill C. diff and performed significantly better than current antibiotics in preventing recurrence. These are significant advantages for patients dealing with this difficult bacterial infection.” 

    The most promising of the Purdue compounds, containing trifluoromethylthio functional group, is HSGN-218. Sintim said it has been shown to be one of the most potent compounds ever produced for use against C. diff. 

    “This is part of our work to create new solutions to treat diseases and infections that are resistant to current treatment options,” said Sintim, who is a member of the Purdue University Center for Cancer Research and the Purdue Institute for Drug Discovery. “This work provides a potential clinical lead for the development of C. diff therapeutics and also highlights dramatic drug potency enhancement via halogen substitution.” 

    The researchers patented their compounds through the Purdue Research Foundation Office of Technology Commercialization, which is looking for partners to advance the technology. George Naclerio, a researcher on Sintim’s team, has been awarded a National Institutes of Health T32 training grant to help facilitate the development of this technology. 

    Purdue University has the release. 

    Latest in Population Health/Care Continuum

    Photo 246006971 © Andrei ASKIRKA | Dreamstime.com
    Regulatory

    New social determinants of health resources released

    Nov. 20, 2023
    Photo 89046596 © Natal'ya Buzuevskaya | Dreamstime.com
    Population Health/Care Continuum

    More than one in three people in the U.S. are at increased risk for type 2 diabetes

    Nov. 20, 2023
    Photo 180279532 © Marek Uliasz | Dreamstime.com
    Population Health/Care Continuum

    FDA announces initiative to ensure pulse oximetry is equitable

    Nov. 20, 2023
    Photo 104326216 | Healthcare © Szefei | Dreamstime.com
    Population Health/Care Continuum

    NIH-funded study says umbilical cord milking appears to be safe in preterm infants born after 28 weeks

    Nov. 9, 2023
    Illustration 83094338 © Lkeskinen0 | Dreamstime.com
    Population Health/Care Continuum

    FDA approves Zepbound (tirzepatide) injection for chronic weight management in adults with obesity

    Nov. 8, 2023
    Healthcare Purchasing News
    https://www.facebook.com/hpnonline
    https://www.linkedin.com/company/healthcare-purchasing-news/
    https://twitter.com/HPN_Online
    • About Us
    • Contact Us
    • Advertise
    • Do Not Sell or Share
    • Privacy Policy
    • Terms & Conditions
    © 2023 Endeavor Business Media, LLC. All rights reserved.
    Endeavor Business Media Logo